GlycoMScan B.V.

GlycoMScan B.V. was founded in 2018 by dr.

Monique van Scherpenzeel who switched her

career from academia into a service company.

She has experience in mass spectrometry

and developed analytical methods for clinical

diagnostics, with an expertise on protein

glycosylation through studying patients

with Congenital Disorders of Glycosylation.

As postdoctoral fellow at the ETH in Zürich

a nucleotide sugar analysis method was

developed, based on their method to study

central carbon metabolism.

We serve national and international pharma and

biotech companies with pharmacokinetics and

analyses to characterize novel drug candidates,

e.g. antibody-drug conjugates. As Eurostar we

were involved in development of well-defined cell

culture media to drive protein glycosylation, and

developed the GLYSEC platform to analyze

cell-surface glycosylation. Both are of high need

in the field of immune-oncology to assist in

finding new drug targets, as well as to improve

drug potency and specificity.

I am impressed by the scientific quality of the

Swiss scientists and therefore I love to work

with them. We already collaborate for years with

EPFL in Lausanne, Asterivir and Orpha Labs. It is

our pleasure to grow our network in Switzerland

to further strengthen our company.